Brief: Race Oncology Says Zantrene Shows Synergy With BRAF & MEK Inhibitors In Treating Melanoma
28/06/2022 01:04
June 28 (Reuters) - Race Oncology Ltd RAC.AX :
* ZANTRENE SHOWS IMPRESSIVE SYNERGY WITH BRAF & MEK
INHIBITORS IN
TREATING MELANOMA
Source text for Eikon: ID:nASX2d8xqd
Further company coverage: RAC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Racura Oncology
See all newsAustralia's Racura Oncology jumps most in a month after raising $24 million
Brief: Racura Oncology Says Emerging Companies Specialist Invests In Racura
Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
Australia's Racura Oncology gains on Purdue University cancer study collab
Brief: Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220